Impact of ocular toxicities associated with belantamab mafodotin treatment in patients with RRMM

In the DREAMM-7 and DREAMM-8 phase III trials, belantamab mafodotin (belamaf) combined with standard therapies demonstrated statistically significant and clinically meaningful progression-free survival (PFS) benefit compared with standard-of-care regimens in patients with relapsed/refractory multiple myeloma (RRMM) after ≥1 prior line of therapy.^1-3 While ocular events were common in both trials, they were effectively managed with dose modifications and were generally reversible with adequate follow-up, allowing patients to remain on treatment and experience clinical benefits. 

Here, we present a visual abstract summarizing the ocular events associated with belamaf and the impact of dose modifications on safety and efficacy, as well as patient-reported outcomes.^1–4

Key learnings: 

• Most patients experienced Grade 2 or 3 ocular events in both trials, which were managed with protocol-recommended dose modifications.³

• Dose delays were common, with the median time between doses extending to every 8 and 12 weeks in DREAMM-7 and DREAMM-8, respectively.³

• Despite dose modifications, efficacy was maintained; almost all patients who responded to treatment experienced ≥1 dose delay.³

• In both studies, patients who required ≥1 extended dose delay of ≥12 weeks had robust PFS.

• The majority of patients did not report having to stop driving or reading throughout treatment.³

• In patients who experienced a bilateral change of BCVA decline to 20/50 or worse, health-related quality of life was stable over time in patients treated with BVd in the DREAMM-7 trial and BPd in the DREAMM-8 trial, and comparable with patients treated with DVd or PVd, respectively.^5,6

• Furthermore, EORTC QLQ-C30 global health status/quality of life, role of function, physical functioning, fatigue and pain were stable over time and consistent between BVd and DVd arms in the DREAMM-7 trial.¹

This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.